No clinically significant drug-resistance mutations in HIV-1 subtype C-infected women after discontinuation of NRTI-based or PI-based HAART for PMTCT in Botswana.
No clinically significant drug-resistance mutations in HIV-1 subtype C-infected women after discontinuation of NRTI-based or PI-based HAART for PMTCT in Botswana.
复制标题
DOI：
10.1097/qai.0b013e31829308f8
复制
发表时间：
2013-08-15
期刊：
影响因子：
--
通讯作者：
Shapiro R
中科院分区：
文献类型：
--
作者：
Souda S;Gaseitsiwe S;Georgette N;Powis K;Moremedi D;Iketleng T;Leidner J;Moffat C;Ogwu A;Lockman S;Moyo S;Mmalane M;Musonda R;Makhema J;Essex M;Shapiro R
在停止抗逆转录病毒疗法以防止艾滋病毒-1母婴传播(PMTCT)后出现抗药性的风险尚不清楚。MMA BANA研究随机治疗--CD4NRT200个/mm~3的幼稚孕妇接受阿巴卡韦/齐多夫定/拉米夫定(三联≥组)或洛匹那韦/利托那韦/齐多夫定/拉米夫定(PI组)治疗。母乳喂养6个月后停药。停药1个月后，29份NRTI ARM样本和25份PI ARM样本成功进行基因分型。没有检测到临床上有意义的抗逆转录病毒耐药性突变。在11名(20%)女性中发现了8个微小的耐药性突变(3个来自NRTI臂，8个来自PI臂)，发生频率与HIV-1 C亚型治疗初始队列中报告的频率相似。
Risk of developing drug resistance after stopping antiretroviral regimens to prevent mother-to-child HIV-1 transmission (PMTCT) is unknown. Mma Bana Study randomized treatment-naïve pregnant women with CD4 ≥200 cells/mm3 to receive either abacavir/zidovudine/lamivudine (triple NRTI arm) or lopinavir/ritonavir/zidovudine/lamivudine (PI arm). Drugs were discontinued after 6 months breastfeeding. One month post-discontinuation, 29 NRTI arm samples and 25 PI arm samples were successfully genotyped. No clinically significant antiretroviral resistance mutations were detected. Eight minor resistance mutations were found among 11(20%) women (3 from NRTI arm, 8 from PI arm), occurring at similar frequencies to those reported in HIV-1 subtype C treatment naive cohorts.